•
Mar 31, 2022
Semler Scientific Q1 2022 Earnings Report
Semler Scientific's financial results for Q1 2022 were reported with revenue increase of 6% and net income of $3.4 million.
Key Takeaways
Semler Scientific reported a revenue increase of 6% to $14.0 million and a net income of $3.4 million for the first quarter of 2022. The company's cash position increased, and a stock buyback program was initiated.
Revenues were $14.0 million, an increase of 6% compared to $13.2 million.
Net income was $3.4 million, or $0.50 per basic share and $0.41 per diluted share, compared to $4.9 million, or $0.73 per basic share and $0.60 per diluted share.
Cash at March 31, 2022 increased to $38.4 million from $26.5 million.
Up to $20.0 million stock buyback program initiated.
Semler Scientific
Semler Scientific
Forward Guidance
Semler Scientific expects continued profitability and cash generation from operating activities, as well as increased spending to support anticipated growth in its business.
Positive Outlook
- Second quarter revenue will range from $14.2 million to $15.2 million
- Annual revenue in 2022 will range from $58.0 million to $60.0 million
- Continued profitability
- Generation of cash from operating activities
- Increased spending to support anticipated growth
Challenges Ahead
- Second quarter operating expense will range from $10.0 million to $10.5 million.
- Annual operating expense will range from $44.0 million to $46.0 million.
- Increased spending to support anticipated growth in its business.
- Uncertainty created by the ongoing COVID-19 pandemic
- Insurance plans and other customers may not continue to license its cardiovascular testing products